Cargando…

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

BACKGROUND: Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice. METHODS: A non-exhaustive systematic review wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Méndez-Vidal, María José, Molina, Áurea, Anido, Urbano, Chirivella, Isabel, Etxaniz, Olatz, Fernández-Parra, Eva, Guix, Marta, Hernández, Carolina, Lambea, Julio, Montesa, Álvaro, Pinto, Álvaro, Ros, Silverio, Gallardo, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258404/ https://www.ncbi.nlm.nih.gov/pubmed/30477570 http://dx.doi.org/10.1186/s40360-018-0264-8

Ejemplares similares

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
por: Puente, Javier, et al.
Publicado: (2020)

Dificultades en la enseñanza de la neurología y las consecuencias académicas de la pandemia de la COVID-19. Réplica
por: Lambea-Gil, Álvaro
Publicado: (2023)

Neurology teaching difficulties and the academic consequences of the COVID-19 pandemic. Reply
por: Lambea-Gil, Álvaro
Publicado: (2023)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
por: Katz, D., et al.
Publicado: (2016)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pazopanib induced hand-foot syndrome
por: Sundriyal, Deepak, et al.
Publicado: (2015)

Pazopanib-Induced Alopecia, an Underestimated Toxicity?
por: Biondo, Andrea, et al.
Publicado: (2015)

Pazopanib-Induced Severe Acute Pancreatitis
por: Kawakubo, Kazumichi, et al.
Publicado: (2015)

Thrombotic Thrombocytopenic Purpura Associated with Pazopanib
por: Syed, Umer, et al.
Publicado: (2018)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

Posterior Reversible Leukoencephalopathy Syndrome Associated with Pazopanib
por: Foerster, Robert, et al.
Publicado: (2013)

Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib
por: Chelis, Leonidas, et al.
Publicado: (2012)

Pazopanib and pancreatic toxicity: a case report
por: Russano, Marco, et al.
Publicado: (2015)

Pazopanib radio-sensitization of human sarcoma tumors
por: Wang, Feng, et al.
Publicado: (2018)

Pazopanib-induced Endothelial Injury with Podocyte Changes
por: Maruyama, Keisuke, et al.
Publicado: (2017)

Rapid hair depigmentation in patient treated with pazopanib
por: Šeparović, Robert, et al.
Publicado: (2018)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Interstitial Lung Disease Induced by Pazopanib Treatment
por: Ide, Shotaro, et al.
Publicado: (2017)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
por: Amaro, Filipa, et al.
Publicado: (2022)

Cronotaraxis como síntoma guía de un infarto talámico medial
por: Espinosa-Rueda, Judith, et al.
Publicado: (2022)

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors
por: Juliachs, Mercè, et al.
Publicado: (2013)

An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)
por: Mehta, C R, et al.
Publicado: (2019)

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021)

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
por: Jones, Robin L., et al.
Publicado: (2022)

Neural Crest Stem Cells from Dental Tissues: A New Hope for Dental and Neural Regeneration
por: Ibarretxe, Gaskon, et al.
Publicado: (2012)

Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2021)

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
por: Méndez-Vidal, María José, et al.
Publicado: (2023)

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists
por: Fernández, Ovidio, et al.
Publicado: (2022)

Guardias médicas durante la formación del residente de neurología en España: cambios en la última década
por: Lambea-Gil, Álvaro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3sat2698jrpieg4q9j6srcq909